RITUXIMAB DELAYS WOUND HEALING AND DECREASES WHITE BLOOD CELL COUNT IN MALE MICE

SELMAN M  SELMAN; Majid K Bashara; Ahmed Raji; Ouday H Kadhum

doi:10.22159/ajpcr.2017.v10i3.15458

Authors

SELMAN M SELMAN College of MedicineUniversity of Babylon
Majid K Bashara
Ahmed Raji
Ouday H Kadhum

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i3.15458

Abstract

ABSTRACT
Objective: The aims of this research are to evaluate the effect of rituximab on wound healing, some hematological parameters, histological changes in
wound healing, and histopathological changes in some organs in male mice.
Methods: Totally, 15 adult male mice (25-30 g) were enrolled in this study. Animals were kept in the animal house College of Medicine/University
of Babylon, and the temperature was controlled on 25Â°C and 14 hrs light and 10 hrs dark cycles. The animals were provided with standard diet and
water ad libitum. The animals were divided randomly into 3 groups, five mice in each group, Group 1 (control group) received no treatment, Group 2
received rituximab 1 m/kg, IP, at days 0, 5, and 10 after wounding, in Group 3, rituximab was topically applied to the wound at days 0, 5, and 10 after
wounding.
Results: The results yield that the wound healing significantly decreased (p<0.05) in Groups 2 and 3 as compared to control group. While the results
regarding white blood cells (WBCs) count, there is a significant decrease in WBC count in Group 2 (p>0.05). Platelets and red blood cell count in
significantly increased in Group 3 as compared to control group (p<0.05). There were no histopathological changes in the skin, kidneys, and spleen.
In liver, nonsignificant histopathological changes (p>0.05) found in Group 2 and 3 as compared to control group.
Conclusion: Rituximab delays wound healing and reduces WBC count in male mice.
Keywords: Rituximab, Wound healing, Lymphocyte, CD20, White blood cells, Mice.

Downloads

Download data is not yet available.

Author Biography

SELMAN M SELMAN, College of MedicineUniversity of Babylon

Department of Pharmacology/ Lecturer

References

REFERENCES

Rieger S, Zhao H, Martin P, Abe K, Lisse TS. The role of nuclear hormone receptors in cutaneous wound repair. Cell Biochem Funct 2015;33(1):1-13.

Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg 1998;176 2A Suppl:26S-38.

Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013;93:327-58.

Greenhalgh DG. The role of apoptosis in wound healing. Int J Biochem Cell Biol 1998;30(9):1019-30.

Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004;36(6):1031-7.

Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res 2010;89(3):219-29.

Barnard AR, Regan M, Burke FD, Chung KC, Wilgis EF. Wound healing with medications for rheumatoid arthritis in hand surgery. ISRN Rheumatol 2012;2012:251962.

Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435-45.

McLaughlin P, Grillo-LÃ³pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33.

Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004;30(2):393-403, viii.

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84(8):2457-66.

Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004;77(4):542-8.

Genberg H, Hansson A, Wernerson A, Wennberg L, TydÃ©n G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6(10):2418-28.

Arroyo-Ãvila M, Fred-JimÃ©nez RM, VilÃ¡ LM. Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia. Case Rep Rheumatol 2015;2015:616787.

Weyrich AS, Zimmerman GA. Platelets: Signaling cells in the immune continuum. Trends Immunol 2004;25(9):489-95.

Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003;23:2131-7.

Chin-Yee I, Keeney M, Krueger L, Dietz G, Moses G. Supernatant from stored red cells activates neutrophils. Transfus Med 1998;8(1):49-56.

Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341(10):738-46.

DeLeve L, Kaplowitz N, editors. Drug-Induced Liver Disease. 3rd ed. Waltham, MA: Academic Press; 2013. p. 776.

Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, et al. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 2005;80(1):43-5.

Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013;27(5):273-80.

Dunleavy K, Tay K, Wilson WH. Rituximab-associated neutropenia. Semin Hematol 2010;47(2):180-6.

Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: A long-term follow-up analysis. Ann Hematol 2007;86(12):871-7.

Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98(4):952-7.